These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11756944)

  • 1. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.
    Ahmed AR; Sami N
    J Am Acad Dermatol; 2002 Jan; 46(1):42-9. PubMed ID: 11756944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Nov; 45(5):679-90. PubMed ID: 11606916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current biologics in treatment of pemphigus foliaceus: a systematic review.
    Carver CA; Kalesinskas M; Ahmed AR
    Front Immunol; 2023; 14():1267668. PubMed ID: 37901249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N; Qureshi A; Ruocco E; Ahmed AR
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four mild but refractory cases of pemphigus foliaceus successfully treated with intravenous immunoglobulin.
    Kawakami T; Koga H; Saruta H; Ueda A; Inoue Y; Soma Y; Ishii N; Hashimoto T
    J Dermatol; 2013 Nov; 40(11):869-73. PubMed ID: 24127870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
    Grando SA
    Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid.
    Sami N; Bhol KC; Razzaque Ahmed A
    Clin Immunol; 2002 Jan; 102(1):59-67. PubMed ID: 11781068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment.
    Ahmed AR
    J Am Acad Dermatol; 2001 Dec; 45(6):825-35. PubMed ID: 11712025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of current data on the use of intravenous immunoglobulins in management of pemphigus vulgaris.
    Engineer L; Bhol KC; Ahmed AR
    J Am Acad Dermatol; 2000 Dec; 43(6):1049-57. PubMed ID: 11100022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
    Mignogna MD; Leuci S; Fedele S; Ruoppo E; Adamo D; Russo G; Pagliuca R
    Am J Clin Dermatol; 2008; 9(5):323-31. PubMed ID: 18717608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and intravenous immunoglobulin as alternatives to long-term systemic corticosteroids in the treatment of pemphigus: a single center case series of 63 patients.
    Brown AE; Motaparthi K; Hsu S
    Dermatol Online J; 2018 Jan; 23(12):. PubMed ID: 29447653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of juvenile pemphigus vulgaris with intravenous immunoglobulins].
    Szép Z; Danilla T; Buchvald D
    Cas Lek Cesk; 2005; 144(10):700-3. PubMed ID: 16279438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of IVIg treatment in severe pemphigus vulgaris.
    Baum S; Scope A; Barzilai A; Azizi E; Trau H
    J Eur Acad Dermatol Venereol; 2006 May; 20(5):548-52. PubMed ID: 16684282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and immunomodulatory effects.
    Svecova D
    Australas J Dermatol; 2016 May; 57(2):141-4. PubMed ID: 26581165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of high-dose intravenous immunoglobulin therapy in 16 patients with refractory autoimmune blistering skin disease: high efficacy and no serious adverse events.
    Seidling V; Hoffmann JH; Enk AH; Hadaschik EN
    Acta Derm Venereol; 2013 May; 93(3):346-9. PubMed ID: 23073990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eyelid skin involvement in pemphigus foliaceus.
    Daoud YJ; Foster CS; Ahmed R
    Ocul Immunol Inflamm; 2005; 13(5):389-94. PubMed ID: 16419424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.